C A P S Pharmacy

What C A P S Pharmacy does

C A P S Pharmacy (Central Admixture Pharmacy Services, Inc.) is a U.S. sterile injectable compounding company founded in 1991 and operating as a subsidiary of B. Braun Medical Inc. within the B. Braun Group of Companies. It runs the nation's largest network of outsourcing admixture pharmacies, comprising 21 state-licensed 503A regional pharmacies and (as of recent disclosure) two FDA-registered 503B outsourcing facilities in Lehigh Valley, Pennsylvania and Phoenix, Arizona. In 2025, CAPS announced a strategic exit from the 503B business to refocus on its core 503A compounding operations, with a 90-day transition period for 503B customers.

The company's core products include custom patient-specific parenteral nutrition (PN) solutions, cardioplegia solutions for cardiac surgery, pre-filled anesthesia syringes, and a standardized drug delivery portfolio of premixed IV solutions such as Oxytocin, Magnesium Sulfate, Vancomycin, and Norepinephrine. Compounding operations run in USP <797>-compliant ISO Class 5 cleanrooms within ISO Class 7 buffer zones, with 503B facilities additionally operating under cGMP with the proprietary Test, Hold and Release (THR) program providing 100% sterility, endotoxin, and potency release testing using BacT/ALERT microbial detection. Supporting technology includes the proprietary CAPSLink online ordering portal with EHR PDF integration and a calcium-phosphate solubility curve screening window for PN formulations, barcoded manual-add safety checks, and an integration with Kit Check for RFID-tagged pre-filled syringes.

CAPS generates revenue through enterprise contracts with U.S. hospitals, outpatient facilities, and home infusion providers via recurring daily delivery of patient-specific sterile preparations (503A), transaction-based batch anticipatory compounding (503B, now being wound down), professional consulting services through CAPS Consulting and ReadyCheck 797/800 assessments, and PN clinical training programs. Pricing is quote-based and not publicly disclosed, with a national Premier Inc. group purchasing agreement (January 2019) anchoring enterprise access. The company goes to market through direct enterprise field sales, healthcare industry tradeshows (ASHP, AmSECT, NHIA), and content marketing via the CAPS Compounding Insights newsletter and podcast, with daily direct delivery plus same-day and next-day options serving as the core distribution model.

Name

C A P S Pharmacy

Legal name

Central Admixture Pharmacy Services, Inc.

Website

https://capspharmacy.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

501–1,000 employees

Short description

C A P S Pharmacy (Central Admixture Pharmacy Services, Inc.) is a U.S. sterile injectable compounder and subsidiary of B. Braun Medical Inc., operating the nation's largest network of outsourcing admixture pharmacies. It delivers customized 503A compounded sterile preparations, primarily parenteral nutrition and ready-to-use IV products, to hospitals and outpatient providers across 21 U.S. locations.

Ownership category

akta.pro rank

Product category

Compounding Pharmacy Services

NAICS

Pharmacies and Drug Retailers (456110)

SIC

Services-Health Services (8000)

akta.pro primary industry

Hospital & Health-System Pharmacies (Inpatient/Outpatient) (HLAFALAB)

akta.pro secondary industries

Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG), Specialty Pharmacies (Complex/High-Cost Therapies) (HLAFALAC)

Keywords

• Sterile compounding pharmacy
• Hospital admixture services
• Parenteral nutrition solutions
• Outsourced sterile preparations
• 503A pharmacy services

Headquarters

HQ city

Allentown

HQ country

United States

HQ region

North America

Offices24 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. 503A Patient-Specific Compounding Services: Customized, patient-specific compounded sterile preparations dispensed upon receipt of a prescription. Services include parenteral nutrition (PN), patient-specific drug doses, IVPB, and syringes. Delivered daily from 21 regional pharmacies to hospital and outpatient pharmacy customers.
2. 503B Batch Compounding Services: Non-patient-specific, anticipatory batch compounding under cGMP regulations including 100% release testing. Products include cardioplegia, anesthesia syringes, standardized drug delivery, and neonatal PN starter bags.
3. CAPS Consulting Services: Professional consulting services for sterile compounding compliance including ReadyCheck 797, ReadyCheck 800 assessments, USP compliance, and remediation projects.
4. PN Clinical Training Services: Web-based training program for pharmacists and clinicians on parenteral nutrition including patient identification, PN formulation design, and patient monitoring.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

CAPS (Central Admixture Pharmacy Services, Inc.) is the nation's largest network of outsourcing admixture pharmacies, providing customized, patient-specific compounded sterile preparations (503A) such as parenteral nutrition, cardioplegia solutions, pre-filled anesthesia syringes, and standardized premixed drug delivery to hospital pharmacies and outpatient facilities. The company supports customers with the proprietary CAPSLink ordering platform, daily direct delivery from 21 regional pharmacies, and complementary sterile compounding consulting and parenteral nutrition clinical training services.

Product overview

CAPS (Central Admixture Pharmacy Services) is the nation's largest network of outsourcing admixture pharmacies offering a portfolio of sterile compounding products and services. The core offerings include custom patient-specific Parenteral Nutrition (PN), Cardioplegia solutions for cardiac surgery, Pre-filled Anesthesia Syringes, and Standardized Drug Delivery (premixed IV solutions). These products are supported by the proprietary CAPSLink ordering platform and complemented by CAPS Consulting services (including ReadyCheck 797/800 compliance assessments) and PN Clinical Training Services. CAPS operates under both 503A (patient-specific) and 503B (batch/outsourcing) regulatory frameworks with 21 regional 503A pharmacies and 2 FDA-registered 503B outsourcing facilities. The company also offers the Test, Hold and Release (THR) quality assurance program for batch release testing.

Differentiator

Problem solved

Functional benefit

Brands

• Test, Hold and Release (THR): CAPS' quality assurance program implementing cGMP level release testing standards for 503B facilities engaged in anticipatory compounding.
• CAPS Consulting
• ReadyCheck
• CAPS Compounding Insights
• CAPSLink
• CAPS PN Clinical Training Services

Products and services

• Parenteral Nutrition (PN) Custom, patient-specific parenteral nutrition solutions designed to meet unique nutritional needs of individual patients, compounded daily at 503A regional pharmacies and delivered to hospital and outpatient pharmacy customers.
• Cardioplegia Solutions Cardioplegia solutions for cardiac surgery, including Blood Cardioplegia Formulas, Crystalloid Cardioplegia Formulas, del Nido formula, and Microplegia, with batch level release testing and extended beyond use dating for hospital cardiac surgery teams.
• Pre-filled Anesthesia Syringes Pre-filled, labeled anesthesia syringes available in frequently used drug concentrations and fill volumes with ASTM color-coded labels, tamper-evident caps, and 90-day extended beyond-use dating. Includes Atropine, Bupivacaine, Ephedrine, Fentanyl, Glycopyrrolate, Ketamine, Lidocaine, Neostigmine, Phenylephrine, Rocuronium, Vecuronium, and Succinylcholine.
• Standardized Drug Delivery Ready-to-use premixed drug services and compounded sterile preparations with validated, extended beyond-use dating for labor and delivery, critical care, antibiotics, and other hospital use cases, including Oxytocin, Magnesium Sulfate, Calcium Gluconate, Potassium Phosphate, Vancomycin, Diltiazem, Epinephrine, Norepinephrine, Phenylephrine, and Tromethamine.
• CAPSLink Online Ordering Portal Proprietary web-based online ordering portal that enables secure ordering with built-in safety checks, EHR PDF integration, a calcium-phosphate solubility curve window for PN formulation screening, and no equipment installation required.
• CAPS Consulting Services Sterile compounding consulting services including ReadyCheck 797 and ReadyCheck 800 compliance assessments, USP <797>, USP <800>, and 503B outsourcing compliance work, supported by over 25 years of CAPS pharmacy and clean-room experience.
• CAPS PN Clinical Training Services Web-based training program for pharmacists and clinicians to identify patients appropriate for parenteral nutrition, design PN formulations, monitor patients for tolerance, and understand PN complications, supplemented by clinical liaison services.

Quantifiable outcome

• Hospitals can redeploy pharmacist labor from compounding to clinical activities such as managing patient outcomes and pharmaceutical care interventions

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Scale indicators7 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• QuVa Pharma: QuVa is one of the largest US 503B outsourcing sterile compounding pharmacies, competing head-to-head with CAPS on batch-prepared anesthesia syringes, cardioplegia, and standardized IV admixtures for hospital systems. Direct competitor in both products and customer base.
• Pharmedium Services (B. Braun): Pharmedium, acquired by B. Braun in 2015, operates the largest 503B outsourcing network in the US for sterile preparations and IV admixtures. Sister company to CAPS within the B. Braun portfolio with overlapping 503B batch compounding services.
• JCB Labs (Wells Pharma): JCB Labs is an FDA-registered 503B outsourcing sterile compounding pharmacy serving hospital and outpatient customers with prefilled syringes and batched CSPs. Direct 503B peer competing for similar hospital pharmacy contracts.
• Leiters Health: Leiters is an FDA-registered 503B outsourcing facility specializing in sterile admixture services for hospitals and health systems, including pre-filled syringes and ready-to-administer preparations. Direct 503B competitor to CAPS, particularly post-CAPS 503B wind-down.
• Olympia Pharmaceuticals: Olympia operates an FDA-registered 503B outsourcing facility providing sterile admixture services, pre-filled syringes, and batch-compounded sterile preparations to hospital pharmacies nationally. Direct competitor in the 503B outsourcing segment CAPS is exiting.

Broad incumbents

• Baxter International: Baxter is a global manufacturer of IV solutions, premixed drugs, and hospital pharmacy products - including large-volume parenterals that overlap with CAPS' Standardized Drug Delivery offerings. Broad incumbent in hospital pharmacy supply with comparable customer relationships at acute-care hospitals.
• ICU Medical: ICU Medical manufactures IV therapy, infusion, and compounding-related products including ready-to-administer premixed IV solutions and closed-system transfer devices for hospital pharmacies. Broad incumbent adjacent to CAPS' premixed drug and anesthesia syringe categories.
• B. Braun Medical Inc. B. Braun Medical is CAPS' parent company and a global manufacturer of IV solutions, infusion pumps, and sterile compounding inputs (including the CAPS-served PN components). Owns Pharmedium as a sister 503B asset and is the ultimate strategic decision-maker for CAPS.

Others

• Omnicell: Omnicell provides hospital pharmacy automation, IV compounding workflow software, and medication management technology that complements or competes with outsourced sterile compounding services like CAPS. Adjacent ecosystem player in hospital pharmacy with comparable enterprise hospital sales motion.

Emerging players

• Revelation Pharma: Revelation Pharma operates a network of 503A and 503B compounding pharmacies across the US focused on sterile preparations for hospital and alternate-site customers. Emerging national platform competing with CAPS in outsourced sterile compounding.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/capps-pharmacy

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about C A P S Pharmacy